Non-gastric extra-nodal marginal zone lymphomas--a single centre experience on 76 patients.
In the present study, we assessed the clinical and pathological data of 76 patients with the diagnosis of non-gastric extranodal marginal zone B-cell lymphoma. The most commonly affected sites were salivary glands, skin, ocular adnexa, lung, intestine and Waldeyer's ring. Ann Arbor stage I disease was present in 39 patients (51%), stage II in 10 (13%) and stage IV in 27 (36%). In 17 cases (21%), the lymphoma presented at multiple mucosal sites. Lymph node and bone marrow involvement were present in 21% and 16%, respectively. Most cases were in the low or low-intermediate risk group. Treatment was heterogeneous and included chlorambucil in 59% either alone or in combination with other agents. Complete and partial remission was achieved in 79% and 7%, respectively, with an overall response rate of 86%. The 5- and 10-year overall survival and cause-specific survival rates were 94%, 82% and 95%, 91%, respectively. The 5- and 10-year progression free survival was 56% and 41%, respectively. The only feature associated with inferior outcome was disease localisation to the lung.
Kalpadakis
Christina
C
Department of Haematology, University of Crete, Medical School, University Hospital of Heraklion, Heraklion Crete, Greece.
Pangalis
Gerassimos A
GA
Vassilakopoulos
Theodoros P
TP
Kyrtsonis
Maria-Christina
MC
Siakantaris
Marina P
MP
Kontopidou
Flora N
FN
Korkolopoulou
Penelope
P
Bobotsis
Panagia
P
Sahanas
Sotirios
S
Tzenou
Tatiana
T
Anagnostou
Dimitra
D
Dimitriadou
Evangelia
E
Yiakoumis
Xanthi
X
Patsouris
Evangelos
E
Roussou
Panagiota
P
Panayiotidis
Panayiotis
P
Papadaki
Eleni
E
Angelopoulou
Maria K
MK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D002699:Chlorambucil